News

News

06-08

2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

06-08

2026

Sciwind Biosciences to Present Head-to-Head Clinical Data of Ecnoglutide and Innovative Pipeline Progress at ADA 2026

03-06

2026

Sciwind Biosciences Announces Ecnoglutide Injection Approved by China’s National Medical Products Administration (NMPA) for Chronic Weight Management

02-24

2026

Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China

01-30

2026

Sciwind Biosciences Announces Ecnoglutide Injection Approved by China’s National Medical Products Administration (NMPA) for Adult Type 2 Diabetes

01-28

2026

Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications

<
1
2
3
4
5
6
>